BIIB
Price
$134.21
Change
-$1.12 (-0.83%)
Updated
Jul 11 closing price
Capitalization
31.34B
19 days until earnings call
BMY
Price
$46.86
Change
-$1.66 (-3.42%)
Updated
Jul 11 closing price
Capitalization
109.66B
19 days until earnings call
Interact to see
Advertisement

BIIB vs BMY

Header iconBIIB vs BMY Comparison
Open Charts BIIB vs BMYBanner chart's image
Biogen
Price$134.21
Change-$1.12 (-0.83%)
Volume$1.14M
Capitalization31.34B
Bristol-Myers Squibb
Price$46.86
Change-$1.66 (-3.42%)
Volume$13.72M
Capitalization109.66B
BIIB vs BMY Comparison Chart in %
Loading...
BIIB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
BMY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BIIB vs. BMY commentary
Jul 12, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BIIB is a StrongBuy and BMY is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 12, 2025
Stock price -- (BIIB: $135.33 vs. BMY: $46.86)
Brand notoriety: BIIB and BMY are both notable
Both companies represent the Pharmaceuticals: Major industry
Current volume relative to the 65-day Moving Average: BIIB: 66% vs. BMY: 103%
Market capitalization -- BIIB: $31.34B vs. BMY: $109.66B
BIIB [@Pharmaceuticals: Major] is valued at $31.34B. BMY’s [@Pharmaceuticals: Major] market capitalization is $109.66B. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $739.66B to $0. The average market capitalization across the [@Pharmaceuticals: Major] industry is $86.34B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BIIB’s FA Score shows that 0 FA rating(s) are green whileBMY’s FA Score has 2 green FA rating(s).

  • BIIB’s FA Score: 0 green, 5 red.
  • BMY’s FA Score: 2 green, 3 red.
According to our system of comparison, BMY is a better buy in the long-term than BIIB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BIIB’s TA Score shows that 5 TA indicator(s) are bullish while BMY’s TA Score has 4 bullish TA indicator(s).

  • BIIB’s TA Score: 5 bullish, 2 bearish.
  • BMY’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, BIIB is a better buy in the short-term than BMY.

Price Growth

BIIB (@Pharmaceuticals: Major) experienced а +1.85% price change this week, while BMY (@Pharmaceuticals: Major) price change was -0.13% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +1.06%. For the same industry, the average monthly price growth was +0.53%, and the average quarterly price growth was +10.62%.

Reported Earning Dates

BIIB is expected to report earnings on Oct 22, 2025.

BMY is expected to report earnings on Oct 30, 2025.

Industries' Descriptions

@Pharmaceuticals: Major (+1.06% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BMY($110B) has a higher market cap than BIIB($31.3B). BIIB has higher P/E ratio than BMY: BIIB (26.95) vs BMY (13.73). BIIB YTD gains are higher at: -12.235 vs. BMY (-14.211). BMY has higher annual earnings (EBITDA): 19.4B vs. BIIB (2.04B). BMY has more cash in the bank: 12.3B vs. BIIB (1.05B). BIIB has less debt than BMY: BIIB (7.34B) vs BMY (41.5B). BMY has higher revenues than BIIB: BMY (45B) vs BIIB (9.84B).
BIIBBMYBIIB / BMY
Capitalization31.3B110B28%
EBITDA2.04B19.4B11%
Gain YTD-12.235-14.21186%
P/E Ratio26.9513.73196%
Revenue9.84B45B22%
Total Cash1.05B12.3B9%
Total Debt7.34B41.5B18%
FUNDAMENTALS RATINGS
BIIB vs BMY: Fundamental Ratings
BIIB
BMY
OUTLOOK RATING
1..100
6159
VALUATION
overvalued / fair valued / undervalued
1..100
88
Overvalued
5
Undervalued
PROFIT vs RISK RATING
1..100
10094
SMR RATING
1..100
7130
PRICE GROWTH RATING
1..100
6159
P/E GROWTH RATING
1..100
9759
SEASONALITY SCORE
1..100
n/a65

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BMY's Valuation (5) in the Pharmaceuticals Major industry is significantly better than the same rating for BIIB (88) in the Biotechnology industry. This means that BMY’s stock grew significantly faster than BIIB’s over the last 12 months.

BMY's Profit vs Risk Rating (94) in the Pharmaceuticals Major industry is in the same range as BIIB (100) in the Biotechnology industry. This means that BMY’s stock grew similarly to BIIB’s over the last 12 months.

BMY's SMR Rating (30) in the Pharmaceuticals Major industry is somewhat better than the same rating for BIIB (71) in the Biotechnology industry. This means that BMY’s stock grew somewhat faster than BIIB’s over the last 12 months.

BMY's Price Growth Rating (59) in the Pharmaceuticals Major industry is in the same range as BIIB (61) in the Biotechnology industry. This means that BMY’s stock grew similarly to BIIB’s over the last 12 months.

BMY's P/E Growth Rating (59) in the Pharmaceuticals Major industry is somewhat better than the same rating for BIIB (97) in the Biotechnology industry. This means that BMY’s stock grew somewhat faster than BIIB’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BIIBBMY
RSI
ODDS (%)
N/A
Bearish Trend 1 day ago
50%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
76%
Bearish Trend 1 day ago
52%
Momentum
ODDS (%)
Bullish Trend 1 day ago
51%
Bullish Trend 1 day ago
48%
MACD
ODDS (%)
Bullish Trend 1 day ago
49%
Bullish Trend 1 day ago
56%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
54%
Bearish Trend 1 day ago
54%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
55%
Bearish Trend 1 day ago
52%
Advances
ODDS (%)
Bullish Trend 10 days ago
54%
Bullish Trend 2 days ago
55%
Declines
ODDS (%)
Bearish Trend 5 days ago
70%
Bearish Trend 5 days ago
54%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
54%
Bearish Trend 1 day ago
59%
Aroon
ODDS (%)
Bullish Trend 1 day ago
32%
Bullish Trend 1 day ago
44%
View a ticker or compare two or three
Interact to see
Advertisement
BIIB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
BMY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
SPIN29.760.07
+0.23%
SPDR SSGA US Equity Premium Income ETF
DFEB44.85-0.02
-0.04%
FT Vest US Equity Deep Bffr ETF Feb
BSCS20.45-0.01
-0.05%
Invesco BulletShares 2028 Corp Bd ETF
FVC35.56-0.07
-0.20%
First Trust Dorsey Wright Dynamic Foc 5
GMET24.78-0.07
-0.26%
VanEck Green Metals ETF

BIIB and

Correlation & Price change

A.I.dvisor indicates that over the last year, BIIB has been loosely correlated with AMGN. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if BIIB jumps, then AMGN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BIIB
1D Price
Change %
BIIB100%
-0.83%
AMGN - BIIB
56%
Loosely correlated
-1.70%
PFE - BIIB
50%
Loosely correlated
-0.50%
SNY - BIIB
46%
Loosely correlated
-1.48%
NVS - BIIB
44%
Loosely correlated
-2.19%
GSK - BIIB
44%
Loosely correlated
-3.28%
More

BMY and

Correlation & Price change

A.I.dvisor indicates that over the last year, BMY has been loosely correlated with PFE. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if BMY jumps, then PFE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BMY
1D Price
Change %
BMY100%
-3.42%
PFE - BMY
53%
Loosely correlated
-0.50%
GILD - BMY
46%
Loosely correlated
-4.28%
JNJ - BMY
44%
Loosely correlated
-0.50%
AMGN - BMY
43%
Loosely correlated
-1.70%
GSK - BMY
41%
Loosely correlated
-3.28%
More